DRUGS IN DEVELOPMENT FOR DIABETES

1. Diabetes therapy - Akesis Pharmaceuticals.
RDN 05-08 022081 NDN- 226-0019-8281-9

NO-AUTHOR

NAMED COMPANY- Company Originator: Akesis Pharmaceuticals (USA); Company parent: Akesis Pharmaceuticals
SPECIAL INDICATOR- Clinical (Phase Unknown)
UPDATE DATE- 20050214

Clinical (Phase Unknown), USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 022081 .

2. Diabetes therapeutic - Merck & Co.
RDN 05-07 022056 NDN- 226-0019-8011-0

NO-AUTHOR

NAMED COMPANY- Company Originator: Merck & Co (USA); Company parent: Merck & Co
SPECIAL INDICATOR- Phase II
UPDATE DATE- 20050111
SYNONYMS- c-3347

Phase II, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 022056 .

3. Research programme: siRNA diabetes therapy - Sirna Therapeutics.
RDN 05-05 021968 NDN- 226-0019-7401-4

NO-AUTHOR

NAMED COMPANY- Company Originator: Sirna Therapeutics (USA); Company parent: Sirna Therapeutics
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050118
SYNONYMS- siRNA diabetes therapy research programme - Sirna Therapeutics

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .URNA antagonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021968 .

4. Research programme: siRNA diabetes therapy - Sirna Therapeutics.
RDN 05-04 021968 NDN- 226-0019-7241-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Sirna Therapeutics (USA); Company parent: Sirna Therapeutics
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050118
SYNONYMS- siRNA diabetes therapy research programme - Sirna Therapeutics

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .URNA antagonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021968 .

5. Research programme: diabetes therapy - Sanwa Kagaku Kenkyusho/VistaGeTherapeutics.
RDN 05-04 021961 NDN- 226-0019-7171-3
NAMED COMPANY- Company Originator: Sanwa Kagaku Kenkyusho (Japan), VistaGen Therapeutics (USA); Company parent: Suzuken, VistaGen Therapeutics
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050118
SYNONYMS- Diabetes therapy research programme - Sanwa Kagaku Kenkyusho/VistaGenTherapeutics

Preclinical, USA, Type-1 diabetes mellitus.
Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021961 .

6. Research programme: vaccines - FIT Biotech.
RDN 04-52 021859 NDN- 226-0019-6331-4
NO-AUTHOR

NAMED COMPANY- Company Originator: FIT Biotech (Finland); Company parent: FIT Biotech
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041221
SYNONYMS- Diabetes vaccine - FIT Biotech, Hepatitis C vaccine - FIT Biotech, Melanoma vaccine - FIT Biotech, Vaccines research programme - FIT Biotech

Preclinical, Finland, Diabetes mellitus.
Preclinical, Finland, Hepatitis C.
Preclinical, Finland, Malignant melanoma

DRUG DESCRIPTOR- .UImmunostimulants, Immunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes), J7A3 (Hepatitis), L3A (Immunostimulating Agents Excluding Interferons); *A10X (Other Drugs Used in Diabetes), J07B-C (Hepatitis vaccines), L03(Immunostimulants)
RELATED ACCESSION- 021859 .

7. Research programme: diabetes therapy - Taisho Pharmaceutical.
RDN 04-50 021799 NDN- 226-0019-5681-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Taisho Pharmaceutical (Japan); Company parent: Taisho Pharmaceutical
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041206
SYNONYMS- Diabetes therapy research programme - Taisho Pharmaceutical, TS 033, TS-033

Preclinical, Japan, Type-1 diabetes mellitus.
Preclinical, Japan, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021799 .

8. Research programme: intranasal diabetes therapy - Nastech Pharmaceutical.
RDN 04-49 021774 NDN- 226-0019-5481-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Unknown (Unknown), Nastech Pharmaceutical Company (USA); Company parent: Nastech Pharmaceutical Company, Unknown
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041130
SYNONYMS- Intranasal diabetes therapy research programme - Nastech Pharmaceutical

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021774 .

9. Research programme: diabetes therapy - Glenmark Pharmaceuticals.
RDN 04-44 021640 NDN- 226-0019-3921-5
NO-AUTHOR

NAMED COMPANY- Company Originator: Glenmark Pharmaceuticals (India); Company parent: Glenmark Pharmaceuticals
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041026
SYNONYMS- Diabetes therapy research programme - Glenmark Pharmaceuticals, GRC 8087

Preclinical, India, Diabetes mellitus

DRUG DESCRIPTOR- .UDipeptidyl peptidase IV inhibitors, Protease inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021640 .

10. Research programme: diabetes therapy - LifeScan/Sangamo BiosSciences
RDN 04-51 021538 NDN- 226-0019-3051-1
NO-AUTHOR

NAMED COMPANY- Company Originator: LifeScan (USA), Sangamo BioSciences (USA); Company parent: Johnson & Johnson, Sangamo BioSciences
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041216
SYNONYMS- Diabetes therapy research programme - Life Sciences/Sangamo BioSciences

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021538 .

11. Research programme: diabetes therapy - Biovitrum.
RDN 04-39 021433 NDN- 226-0019-2231-0
NO-AUTHOR

NAMED COMPANY- Company Originator: Biovitrum (Sweden); Company parent: Biovitrum
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040907
SYNONYMS- Diabetes therapy research programme - Biovitrum

Preclinical, Sweden, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UFatty acid-binding protein inhibitors, Fatty acid transport protein inhibitors, Protein inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021433 .

12. Research programme: diabetes therapy - TransTech Pharma.
RDN 04-31 021204 NDN- 226-0019-0341-9
NO-AUTHOR

NAMED COMPANY- Company Originator: TransTech Pharma (USA); Company parent: TransTech Pharma
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040727
SYNONYMS- Diabetes therapy research programme - TransTech Pharma

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UPhosphatase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021204 .

13. Research programme: diabetes therapy - Biovitrum/Medivir.
RDN 04-33 021168 NDN- 226-0019-0041-5
NO-AUTHOR

NAMED COMPANY- Company Originator: Biovitrum (Sweden), Medivir AB (Sweden); Company parent: Biovitrum, Medivir AB
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040721
SYNONYMS- Diabetes therapy research programme - Biovitrum/Medivir

Preclinical, Sweden, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021168 .

14. Research programme: diabetes therapy - Chipcreen Biosciences.
RDN 04-31 021164 NDN- 226-0019-0011-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Chipscreen Biosciences (China); Company parent: Chipscreen Biosciences
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040720
SYNONYMS- CS00018, CS00088, CS00098, Diabetes therapy research programme - Chipscreen Biosciences

Preclinical, China, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UPeroxisome proliferator-activated receptor alpha agonists, Peroxisomeproliferator-activated receptor agonists, Peroxisome proliferator- activated receptor gamma agonists, Peroxisome proliferator-activated receptor agonists, Retinoid X receptor agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 021164 .

15. Research programme: diabetes therapy - Hybrigenics.
RDN 04-28 020981 NDN- 226-0018-8251-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Hybrigenics (France); Company parent: Hybrigenics
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040701
SYNONYMS- Diabetes therapy research programme - Hybrigenics

Preclinical, France, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UCalcium channel agonists, Ion channel agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 020981 .

16. Research programme: aldose reductase inhibitors - The Institute for Diabetes Discovery.
RDN 04-27 020960 NDN- 226-0018-8091-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Institute for Diabetes Discovery LLC (USA); Company parent: The Institutes for Pharmaceutical Discovery LLC
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040630
SYNONYMS- Aldose reductase inhibitors research programme - The Institute for Diabetes Discovery

Preclinical, USA, Diabetic neuropathies

DRUG DESCRIPTOR- .UAldose reductase inhibitors, Reductase inhibitors, Oxidoreductase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X-A (Aldose reductase inhibitors)
RELATED ACCESSION- 020960 .

17. Research programme: protein tyrosine phosphatase-1B inhibitors - The Institute for Diabetes Discovery.
RDN 04-25 020868 NDN- 226-0018-7291-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Institute for Diabetes Discovery LLC (USA); Company parent: The Institutes for Pharmaceutical Discovery LLC
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040617
SYNONYMS- IDD-3, IDD-3-IDD, IDD-3-Institute for Diabetes Discovery, Protein tyrosine phosphatase-1B inhibitors research programme - The Institutefor Diabetes Discovery

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UProtein tyrosine phosphatase inhibitors, Phosphatase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 020868 .

18. Research programme: diabetes therapy - SK Bio-Pharmaceuticals.
RDN 04-14 020468 NDN- 226-0018-3671-8
NO-AUTHOR

NAMED COMPANY- Company Originator: SK Bio-Pharmaceuticals (South Korea); Company parent: SK Corporation
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040325
SYNONYMS- Diabetes therapy research programme - SK Bio-Pharmaceuticals, YKP 4120, YKP4120

Preclinical, South Korea, Diabetes mellitus

DRUG DESCRIPTOR- .UPeroxisome proliferator-activated receptor gamma agonists, Peroxisomeproliferator-activated receptor agonists, Insulin sensitisers..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 020468 .

19. Research programme: diabetes therapy - Metabolic Pharmaceuticals.
RDN 04-17 020349 NDN- 226-0018-2571-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Metabolic Pharmaceuticals (Australia); Company parent: Metabolic Pharmaceuticals
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040303
SYNONYMS- ADD 9918/ADD 9922, ADD9918/ADD9922, Diabetes therapy research programme - Metabolic Pharmaceuticals

Preclinical, Australia, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 020349 .

20. Research programme: diabetes therapy - AGT Biosciences/Starpharma Pooled Development.
RDN 03-43 019735 NDN- 226-0017-7181-6
NO-AUTHOR

NAMED COMPANY- Company Originator: AGT Biosciences (Australia), Starpharma Pooled Development (Australia; Company parent: AGT Biosciences, Starpharma Pooled Development
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20031023
SYNONYMS- Diabetes therapy research programme - AGT Biosciences/Starpharma Pooled Development

Preclinical, Australia, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019735 .

21. Research programme: diabetes therapy - ChemGenex Pharmaceuticals/ Starpharma Pooled Development.
RDN 04-44 019735 NDN- 226-0017-7101-4
NO-AUTHOR

NAMED COMPANY- Company Originator: ChemGenex Pharmaceuticals (Australia), Starpharma Pooled Development (Australia); Company parent: ChemGenex Pharmaceuticals, Starpharma Pooled Development
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041021
SYNONYMS- Diabetes therapy research programme - ChemGenex Pharmaceuticals/ Starpharma Pooled Development

Preclinical, Australia, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019735 .

22. Research programme: diabetes therapeutics and diagnostics - ParAlleleBioScience/Roche.
RDN 03-38 019637 NDN- 226-0017-6141-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Roche (Switzerland), ParAllele BioScience (USA), Roche (USA); Company parent: ParAllele BioScience, Roche
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030918
SYNONYMS- diabetes therapeutics and diagnostics research programme - ParAllele BioScience/Roche

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019637 .

23. Research programme: diabetes therapy - NPS Pharmaceuticals.
RDN 05-05 019298 NDN- 226-0017-3151-3
NO-AUTHOR

NAMED COMPANY- Company Originator: NPS Pharmaceuticals (USA); Company parent: NPS Pharmaceuticals
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050124
SYNONYMS- diabetes therapy research programme - NPS Pharmaceuticals, R 467

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UCalcium channel agonists, Ion channel agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019298 .

24. Diabetes gene therapy - Baylor College of Medicine.
RDN 03-42 019209 NDN- 226-0017-2261-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Baylor College of Medicine (USA); Company parent: Baylor College of Medicine
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030630
SYNONYMS- Ad-Neurod-Btc gene therapy

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UInsulinotropin agonists, Releasing hormone agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019209 .

25. Research programme: diabetes therapy - STIL BioTechnologies.
RDN 03-29 019184 NDN- 226-0017-2031-8
NO-AUTHOR

NAMED COMPANY- Company Originator: STIL BioTechnologies (Israel); Company parent: STIL BioTechnologies
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030711
SYNONYMS- SB 25, SB 29

Preclinical, Israel, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019184 .

26. Glucagon-like peptide-1 gene therapy - Genzyme Corporation.
RDN 03-36 019004 NDN- 226-0017-0501-2
NO-AUTHOR

NAMED COMPANY- Company Originator: Genzyme Corporation (USA); Company parent: Genzyme Corporation
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030902
SYNONYMS- Type 2 diabetes gene therapy

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UGlucagon-like peptide-1 agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 019004 .

27. Research programme: diabetes therapy - CombinatoRx.
RDN 03-24 018957 NDN- 226-0017-0181-3
NO-AUTHOR

NAMED COMPANY- Company Originator: CombinatoRx (USA); Company parent: CombinatoRx
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030610
SYNONYMS- diabetes therapy research programme - CombinatoRx

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018957 .

28. Research programme: protein tyrosine phosphatase 1B inhibitors - Sunesis.
RDN 04-31 018950 NDN- 226-0017-0131-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Sunesis Pharmaceuticals (USA); Company parent: Sunesis Pharmaceuticals
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040727
SYNONYMS- Protein tyrosine phosphatase 1B inhibitors research programme - Sunesis, PTP-1B inhibitors research programme - Sunesis, Type-2 diabetes therapeutics research programme - Sunesis

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UProtein tyrosine phosphatase inhibitors, Phosphatase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018950 .

29. Research programme: diabetes therapy - Innodia.
RDN 04-25 018893 NDN- 226-0016-9731-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Innodia (Canada); Company parent: Innodia
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040611
SYNONYMS- diabetes therapy research programme - Innodia, ID 1101

Preclinical, Canada, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018893 .

30. Non-acetylated ghrelin - Theratechnologies.
RDN 04-49 018493 NDN- 226-0016-6861-6
NO-AUTHOR

NAMED COMPANY- Company Originator: Theratechnologies (Canada); Company parent: Theratechnologies
SPECIAL INDICATOR- Phase I
UPDATE DATE- 20030730
SYNONYMS- Diabetes therapy research programme - Theratechnologies, Non-acylatedghrelin

Phase I, Canada, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A16A (Other Alimentary Tract and Metabolism Products); *A16A (Other Alimentary Tract and Metabolism Products)
RELATED ACCESSION- 018493 .

31. Research programme: diabetes therapy - Kyorin.
RDN 03-24 018449 NDN- 226-0016-6651-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Kyorin Pharmaceutical (Japan); Company parent: Kyorin Pharmaceutical
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030303
SYNONYMS- Diabetes therapy research programme - Kyorin

Preclinical, Scotland, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018449 .

32. Research programme: diabetes gene therapy - DeveloGen.
RDN 03-33 018270 NDN- 226-0016-5451-7
NO-AUTHOR

NAMED COMPANY- Company Originator: DeveloGen (Germany); Company parent: DeveloGen
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20000101

Preclinical, Germany, Diabetes mellitus

DRUG DESCRIPTOR- .UInsulinotropin agonists, Releasing hormone agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018270 .

33. 869682.
RDN 04-52 018020 NDN- 226-0016-2911-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Kissei Pharmaceutical (Japan); Company parent: Kissei Pharmaceutical; Company Licensee: GlaxoSmithKline
SPECIAL INDICATOR- Phase II
UPDATE DATE- 20041220
SYNONYMS- Diabetes therapy research programme - GlaxoSmithKline, KGT, KGT 1251

Phase II, Europe, Diabetes mellitus

DRUG DESCRIPTOR- .USodium-glucose co-transporter inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 018020 .

34. Research programme: diabetes therapy - Aventis/Morphochem.
RDN 04-38 017947 NDN- 226-0016-2451-0
NO-AUTHOR

NAMED COMPANY- Company Originator: Aventis (France), Aventis (Germany), Morphochem AG (Germany); Company parent: Aventis, Morphochem AG
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20030904
SYNONYMS- diabetes therapy research programme - Aventis/Morphochem

No Development Reported, Germany, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017947 .

35. DP-18.
RDN 03-36 017912 NDN- 226-0016-2181-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Human Genome Sciences (USA); Company parent: Human Genome Sciences
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20021008
SYNONYMS- Diabetes Protein-18

Preclinical, USA, Type-1 diabetes mellitus.
Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017912 .

36. Research programme: cardiovascular disease and diabetes - Celera/ Bristol-Myers Squibb.
RDN 02-44 017670 NDN- 226-0016-0451-2
NO-AUTHOR

NAMED COMPANY- Company Originator: Bristol-Myers Squibb (USA), Celera Diagnostics (USA); Company parent: Applied Biosystems - Celera Genomics, Bristol-Myers Squibb
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20021007

Preclinical, USA, Cardiovascular disorders.
Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes), C6A (Other Cardiovascular Products); *A10X (Other Drugs Used in Diabetes), C (Cardiovascular System)
RELATED ACCESSION- 017670 .

37. Research programme: diabetes therapy - ActivX Biosciences/Kyorin.
RDN 05-07 017573 NDN- 226-0015-9631-2
NO-AUTHOR

NAMED COMPANY- Company Originator: Kyorin Pharmaceutical (Japan), ActivX Biosciences (USA); Company parent: Kyorin Pharmaceutical
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050203
SYNONYMS- diabetes therapy research programme - ActivX Biosciences/Kyorin

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017573 .

38. Research programme: diabetes therapy - BioVisioN/Novo Nordisk.
RDN 02-23 017336 NDN- 226-0015-7801-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Novo Nordisk (Denmark), BioVisioN (Germany); Company parent: BioVisioN, Novo Nordisk
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20020530
SYNONYMS- diabetes therapy research programme - BioVisioN/Novo Nordisk

Preclinical, Denmark, Type-2 diabetes mellitus.
Preclinical, Germany, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017336 .

39. Research programme: diabetes therapy - BioVisioN/Novo Nordisk.
RDN 05-09 017336 NDN- 226-0015-7551-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Novo Nordisk (Denmark), BioVisioN (Germany); Company parent: BioVisioN, Novo Nordisk
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20050224
SYNONYMS- Diabetes therapy research programme - BioVisioN/Novo Nordisk

Preclinical, Denmark, Type-2 diabetes mellitus.
Preclinical, Germany, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017336 .

40. Research programme: diabetes therapy - Novo Nordisk/TransTech Pharma
RDN 03-33 017006 NDN- 226-0015-5381-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Novo Nordisk (Denmark), TransTech Pharma (Denmark), TransTech Pharma (USA); Company parent: Novo Nordisk, TransTech Pharma
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030811
SYNONYMS- diabetes therapy research programme - Novo Nordisk/TransTech Pharma

Preclinical, Denmark, Diabetes mellitus.
Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 017006 .

41. Research programme: diabetes therapy - Roche/Vernalis.
RDN 05-04 016912 NDN- 226-0015-4661-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Roche (Switzerland), Vernalis (United Kingdom), Roche (Unknown), Vernalis (Unknown); Company parent: Roche, Vernalis
SPECIAL INDICATOR- Discontinued Preclinical
UPDATE DATE- 20050114
SYNONYMS- diabetes therapy research programme - Roche/Vernalis

Discontinued Preclinical, Unknown, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016912 .

42. Research programme: diabetes therapy - Genentech.
RDN 03-35 016697 NDN- 226-0015-2681-4

NO-AUTHOR

NAMED COMPANY- Company Originator: Genentech (USA), University of North Carolina at Chapel Hill (USA); Company parent: Roche, University of North Carolina
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20030825
SYNONYMS- BP 101

No Development Reported, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UInsulin sensitisers..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016697 .

43. Research programme: diabetes therapy - Immtech.
RDN 03-45 016648 NDN- 226-0015-2201-1 NO-AUTHOR

NAMED COMPANY- Company Originator: Immtech International (USA); Company parent: Immtech International
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20030825
SYNONYMS- diabetes therapy research programme - Immtech

No Development Reported, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UInsulin sensitisers..UUnknown.
..

DESCRIPTOR- *A10B (Oral Antidiabetics); *A10B (Oral Blood Glucose Lowering Drugs)
RELATED ACCESSION- 016648 .

44. Research programme: diabetes therapy - Devgen.
RDN 04-33 016478 NDN- 226-0015-0621-2

NO-AUTHOR

NAMED COMPANY- Company Originator: Devgen (Belgium), Metabolex (USA); Company parent: Devgen, Metabolex
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040804
SYNONYMS- Diabetes therapy research programme - Devgen

Preclinical, Belgium, Diabetes mellitus.
Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016478 .

45. Islet Neogenesis Therapy - Transition Therapeutics.
RDN 05-05 016383 NDN- 226-0014-9771-9
NO-AUTHOR

NAMED COMPANY- Company Originator: Transition Therapeutics (Canada), Transition Therapeutics (United Kingdom); Company parent: Transition Therapeutics; Company Licensee: Novo Nordisk
SPECIAL INDICATOR- Phase I
UPDATE DATE- 20041014
SYNONYMS- Diabetes Islet Neogenesis Therapy - Transition Therapeutics, E1-I.N.Tsup(TM), gastrin + epidermal growth factor

Phase I, United Kingdom, Diabetes mellitus

DRUG DESCRIPTOR- .UGrowth factor agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016383 .

46. CS 917.
RDN 05-07 016169 NDN- 226-0014-7111-0
NO-AUTHOR

NAMED COMPANY- Company Originator: Sankyo (Japan), Metabasis Therapeutics (USA); Company parent: Metabasis Therapeutics, Sankyo
SPECIAL INDICATOR- Phase II
UPDATE DATE- 20050105
SYNONYMS- Diabetes therapy research programme - Metabasis/Sankyo, MB 6322, MB06322, Research programme: diabetes therapy - Metabasis/Sankyo

Phase II, Europe, Type-2 diabetes mellitus.
Phase II, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UGluconeogenesis inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016169 .

47. PV 705.
RDN 03-34 016101 NDN- 226-0014-6461-0
NO-AUTHOR

NAMED COMPANY- Company Originator: International Diabetes Institute (Australia); Company parent: International Diabetes Institute; Company Licensee: GroPep
SPECIAL INDICATOR- Discontinued II
UPDATE DATE- 20020328

Discontinued II, Australia, Diabetic neuropathies

DRUG DESCRIPTOR- .UGrowth factor agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 016101 .

48. Research programme: diabetes therapy - Arena Pharmaceuticals.
RDN 05-03 015929 NDN- 226-0014-4791-2

NO-AUTHOR

NAMED COMPANY- Company Originator: Arena Pharmaceuticals (USA); Company parent: Arena Pharmaceuticals; Company Licensee: Johnson & Johnson Pharmaceutical Research & Development LLC, Ortho-McNeil Pharmaceutical
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20041223
SYNONYMS- 19AJ agonists, 19AJ GPCR agonists, diabetes therapy - Arena Pharmaceuticals

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UG protein-coupled receptor agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015929 .

49. Research programme: type 2 diabetes mellitus therapy - deCODE genetics/Roche.
RDN 04-08 015908 NDN- 226-0014-4591-6
NO-AUTHOR

NAMED COMPANY- Company Originator: deCODE genetics (Iceland), Roche (Switzerland); Company parent: Roche, deCODE genetics
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030814
SYNONYMS- Type 2 diabetes mellitus therapy research programme - deCODE genetics/Roche

Preclinical, Europe, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015908 .

50. Research programme: diabetes/obesity therapy - Institute for DiabetesDiscovery/Kaken.
RDN 03-34 015901 NDN- 226-0014-4521-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Kaken Pharmaceutical (Japan), Institute for Diabetes Discovery LLC (USA); Company parent: Kaken Pharmaceutical, The Institutes for Pharmaceutical Discovery LLC
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030819
SYNONYMS- Diabetes/obesity research programme - Institute for Diabetes Discovery/Kaken

Preclinical, Japan, Diabetes mellitus.
Preclinical, USA, Diabetes mellitus.
Preclinical, Japan, Obesity.
Preclinical, USA, Obesity

DRUG DESCRIPTOR- .UProtein tyrosine phosphatase inhibitors, Phosphatase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes), A8A (Antiobesity Preparations, Excluding Dietetics); *A08A (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015901 .

51. Research programme: diabetes therapy - Incyte Genomics/Odyssey.
RDN 01-22 015849 NDN- 226-0014-4031-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Incyte Genomics (USA), Odyssey Pharmaceuticals (USA); Company parent: Incyte Genomics, Odyssey Pharmaceuticals
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20010524
SYNONYMS- Diabetes therapy research programme - Incyte Genomics/Odyssey

Preclinical, USA, Diabetes mellitus

DRUG DESCRIPTOR- Undefined mechanism.

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015849 .

52. Research programme: diabetes therapy - Crucell.
RDN 05-05 015827 NDN- 226-0014-3831-7
NO-AUTHOR

NAMED COMPANY- Company Originator: Crucell (Netherlands), University Medical Center Utrecht (Netherlands; Company parent: Crucell, University Medical Center Utrecht
SPECIAL INDICATOR- Discontinued Preclinical
UPDATE DATE- 20050126
SYNONYMS- diabetes therapy research programme - Crucell

Discontinued Preclinical, Netherlands, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UIslet amyloid polypeptide aggregation inhibitors, Amylin antagonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes), J7C (All Other Vaccines); *A10X (Other Drugs Used in Diabetes), J07X (Other vaccines)
RELATED ACCESSION- 015827 .

53. Islet cell transplantation diabetes therapy.
RDN 04-28 015820 NDN- 226-0014-3771-5
NO-AUTHOR

NAMED COMPANY- Company Originator: University of Alberta (Canada); Company parent: University of Alberta
SPECIAL INDICATOR- Phase I
UPDATE DATE- 20040706
SYNONYMS- Edmonton Protocol

Phase I, Canada, Type-1 diabetes mellitus.
Phase I, World, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UInsulin receptor activators..UUnknown.
..

DESCRIPTOR- *A10C (Human Insulins and Analogues); *A10A (Insulins and Analogues)
RELATED ACCESSION- 015820 .

54. Metreleptin.
RDN 04-46 015446 NDN- 226-0014-0111-7
NO-AUTHOR

NAMED COMPANY- Company Originator: Howard Hughes Medical Institute (USA), Rockefeller University (USA); Company parent: Howard Hughes Medical Institute, Rockefeller University; Company Licensee: Amgen; Company Other: National Institute of Diabetes and Digestive and Kidney Diseases
SPECIAL INDICATOR- Phase II
UPDATE DATE- 20020305
MOLECULAR FORMULA- C714 H1167 N191 O221 S6
SYNONYMS- r-metHuLeptin, Recombinant methionyl human leptin

Phase II, USA, Obesity.
Clinical (Phase Unknown), USA, Metabolic disorders

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A16A (Other Alimentary Tract and Metabolism Products), A8A (Antiobesity Preparations, Excluding Dietetics); *A08A (Antiobesity Preparations, Excl. Diet Products), A16A (Other Alimentary Tract and Metabolism Products)
CAS REGISTRY/EC NUMBER(S)- *186018-45-1
CHEMICAL NAME- *N-Methionylleptin (human)
RELATED ACCESSION- 015446 .

55. Research programme: diabetes therapy - Bayer.
RDN 03-33 015303 NDN- 226-0013-8731-6
NO-AUTHOR

NAMED COMPANY- Company Originator: Bayer (Germany); Company parent: Bayer
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20010214
SYNONYMS- Diabetes therapy research programme - Bayer, PACAP R3 SA

Preclinical, Germany, Diabetes mellitus

DRUG DESCRIPTOR- .UAdenylate cyclase stimulants, Enzyme stimulants..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015303 .

56. Research programme: diabetes therapy - Digital Gene Technologies.
RDN 03-33 015259 NDN- 226-0013-8291-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Digital Gene Technologies (USA); Company parent: Digital Gene Technologies; Company Other: Harvard Medical School
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20030617
SYNONYMS- diabetes therapy research programme - Digital Gene Technologies, Research programme: gene discovery - Digital Gene Technologies

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 015259 .

57. Research programme: diabetes therapy - Abbott/Metabolex.
RDN 03-32 014309 NDN- 226-0012-9431-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Abbott Laboratories (USA), Metabolex (USA); Company parent: Abbott Laboratories, Metabolex
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20030806
SYNONYMS- Diabetes therapy research programme - Abbott/Metabolex

No Development Reported, USA, Diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 014309 .

58. Lidorestat.
RDN 04-39 013098 NDN- 226-0011-7961-4
NO-AUTHOR

NAMED COMPANY- Company Originator: Institute for Diabetes Discovery LLC (USA); Company parent: The Institutes for Pharmaceutical Discovery LLC
SPECIAL INDICATOR- Clinical (Phase Unknown)
UPDATE DATE- 20040920
MOLECULAR FORMULA- C18 H11 F3 N2 O2 S . H2 O
SYNONYMS- EML 676, IDD 676, lindolrestat, lindorestat

Clinical (Phase Unknown), North America, Diabetic neuropathies

DRUG DESCRIPTOR- .UAldose reductase inhibitors, Reductase inhibitors, Oxidoreductase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X-A (Aldose reductase inhibitors)
CHEMICAL NAME- *1-Indoleacetic acid, 3-(4,5,7-trifluorobenzothiazol-2-yl)-, monohydrate
CAS DESCRIPTOR- *245116-90-9 (unhydrated form)
RELATED ACCESSION- 013098 .

59. Research programme: diabetes therapy - MIGENIX.
RDN 04-40 013074 NDN- 226-0011-7741-0
NO-AUTHOR

NAMED COMPANY- Company Originator: MIGENIX (Canada), MIGENIX (USA); Company parent: MIGENIX
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20040928
SYNONYMS- Diabetes therapy research programme - MIGENIX, MITO 2915, MITO 3384, MITO 4837

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UMitochondrial function enhancers..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 013074 .

60. IDD 598.
RDN 02-36 012574 NDN- 226-0011-3221-7
NO-AUTHOR

NAMED COMPANY- Company Originator: Institut de Genetique et de Biologie Moleculaire et Cellulaire (France), Institute for Diabetes Discovery LLC (USA); Company parent: Institut de Genetique et de Biologie Moleculaire et Cellulaire, The Institutes for Pharmaceutical Discovery LLC
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20020430
MOLECULAR FORMULA- C16 H13 F N2 O5 S

No Development Reported, France, Diabetic complications.
No Development Reported, USA, Diabetic complications

DRUG DESCRIPTOR- .UAldose reductase inhibitors, Reductase inhibitors, Oxidoreductase inhibitors, Enzyme inhibitors..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X-A (Aldose reductase inhibitors)
CHEMICAL NAME- *5-Fluoro-2-(3-nitro-benzythiolcarbamoyl)-phenoxy acetic acid
RELATED ACCESSION- 012574 .

61. Research programme: diabetes therapy - Oxford BioMedica.
RDN 03-33 012286 NDN- 226-0011-0501-5
NO-AUTHOR

NAMED COMPANY- Company Originator: Oxford BioMedica (United Kingdom); Company parent: Oxford BioMedica
SPECIAL INDICATOR- Discontinued Preclinical
UPDATE DATE- 20030813
SYNONYMS- Diabetes therapy research programme - Oxford BioMedica

Discontinued Preclinical, Unknown, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 012286 .

62. Research programme: diabetes therapy - OSI Pharmaceuticals/VanderbiltUniversity.
RDN 03-06 011725 NDN- 226-0010-5301-7
NO-AUTHOR

NAMED COMPANY- Company Originator: OSI Pharmaceuticals (USA), Vanderbilt Diabetes Center (USA); Company parent: OSI Pharmaceuticals, Vanderbilt University School of Medicine; Company Licensee: Tanabe Seiyaku
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 20020626
SYNONYMS- diabetes therapy - OSI Pharmaceuticals/Vanderbilt University

Preclinical, USA, Type-2 diabetes mellitus

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 011725 .

63. Diabetes type 1 vaccine oral - Diamyd Therapeutics.
RDN 02-52 011721 NDN- 226-0010-5261-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Diamyd Therapeutics (Sweden), GTC Biotherapeutics (USA); Company parent: Diamyd Medical, GTC Biotherapeutics
SPECIAL INDICATOR- Suspended Preclinical
UPDATE DATE- 20021015
SYNONYMS- Oramyd

Suspended Preclinical, Sweden, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UImmunostimulants, Immunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 011721 .

64. Diabetes type 1 vaccine - Diamyd Therapeutics.
RDN 04-26 011663 NDN- 226-0010-4711-8
NO-AUTHOR

NAMED COMPANY- Company Originator: Diamyd Therapeutics (Sweden); Company parent: Diamyd Medical
SPECIAL INDICATOR- Phase II
TRADE NAME- Diamyd(TM)
UPDATE DATE- 20040617
SYNONYMS- GAD65, rhGAD65

Phase II, Sweden, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UImmunostimulants, Immunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 011663 .

65. Diabetes type 1 vaccine - BioDiscovery.
RDN 03-06 011220 NDN- 226-0010-0511-6
NO-AUTHOR

NAMED COMPANY- Company Originator: BioDiscovery (Australia), John Curtin School of Medical Research (Australia); Company parent: Australian National University, BioDiscovery
SPECIAL INDICATOR- Phase II
UPDATE DATE- 20020822
SYNONYMS- Q-Vax

Phase II, Australia, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UImmunostimulants, Immunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 011220 .

66. Diabetes type 1 vaccine - Corixa.
RDN 04-52 010394 NDN- 226-0009-2841-7
NO-AUTHOR

NAMED COMPANY- Company Originator: Corixa Corporation (USA); Company parent: Corixa Corporation
SPECIAL INDICATOR- Discontinued Preclinical
UPDATE DATE- 20041220
SYNONYMS- Anervax.DB, DiavaX

Discontinued Preclinical, USA, Type-1 diabetes mellitus

DRUG DESCRIPTOR- .UImmunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 010394 .

67. Research programme: diabetes therapy - DeveloGen.
RDN 01-15 009817 NDN- 226-0008-7751-5
NO-AUTHOR

NAMED COMPANY- Company Originator: DeveloGen (Germany); Company parent: DeveloGen
SPECIAL INDICATOR- Preclinical
UPDATE DATE- 19980219

Preclinical, Germany, Diabetes mellitus

DRUG DESCRIPTOR- Undefined mechanism.

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 009817 .

68. Diabetes type 1 vaccine.
RDN 01-25 008662 NDN- 226-0007-7301-1
NO-AUTHOR

NAMED COMPANY- Company Originator: Nonindustrial source (France); Company parent: Nonindustrial source
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20010615
SYNONYMS- Type I diabetes vaccine

No Development Reported, France, Diabetes mellitus

DRUG DESCRIPTOR- Immunostimulants, Immunomodulators;
Route(s) of Administration: PO.

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 008662 .

69. Neurulin.
RDN 03-06 008578 NDN- 226-0007-6541-3
NO-AUTHOR

NAMED COMPANY- Company Originator: Provalis (United Kingdom); Company parent: Provalis; Company Other: International Diabetes Institute
SPECIAL INDICATOR- Discontinued II
UPDATE DATE- 19991229

Discontinued II, Australia, Diabetic neuropathies

DRUG DESCRIPTOR- .UUndefined mechanism..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 008578 .

70. Diabetes gene therapy.
RDN 03-20 006352 NDN- 226-0005-6161-4

NO-AUTHOR

NAMED COMPANY- Company Originator: Nonindustrial source (Unknown), Nonindustrial source (USA), Pfizer (USA); Company parent: Nonindustrial source, Pfizer
SPECIAL INDICATOR- No Development Reported
UPDATE DATE- 20020719

No Development Reported, USA, Diabetes mellitus.
No Development Reported, World, Diabetes mellitus

DRUG DESCRIPTOR- .UInsulinotropin agonists, Releasing hormone agonists..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 006352 .

71. Diabetes type 1 vaccine - BioSeek.
RDN 04-09 003497 NDN- 226-0003-0211-8
NO-AUTHOR

NAMED COMPANY- Company Originator: University of Florida College of Medicine (USA); Company parent: University of Florida; Company Licensee: BioSeek, Research Corporation Technologies
SPECIAL INDICATOR- Discontinued (Phase Unknown)
UPDATE DATE- 20040223
SYNONYMS- Insulin B chain vaccine

Discontinued (Phase Unknown), USA, Diabetes mellitus

DRUG DESCRIPTOR- .UImmunostimulants, Immunomodulators..UUnknown.
..

DESCRIPTOR- *A10X (Other Drugs Used in Diabetes); *A10X (Other Drugs Used in Diabetes)
RELATED ACCESSION- 003497

The information contained in this report has been obtained from one or more copyrighted sources under the authority of the copyright owners..